Ipsen 과거 수익 실적

ENXTPA:IPN 수익, 비용 및 수입 (EUR Millions )
날짜	수익	수익	G+A 비용	R&D 비용
30 Jun 24	3,435	664	1,157	653
31 Mar 24	3,371	641	1,146	636
31 Dec 23	3,306	617	1,135	619
30 Jun 23	3,282	406	1,105	528
31 Mar 23	3,219	500	1,072	487
31 Dec 22	3,156	593	1,039	445
30 Sep 22	3,053	656	1,007	436
30 Jun 22	2,950	719	975	427
31 Mar 22	2,849	675	946	425
31 Dec 21	2,749	631	916	424
30 Sep 21	2,712	626	923	422
30 Jun 21	2,676	622	931	420
31 Mar 21	2,681	585	951	413
31 Dec 20	2,686	548	972	406
30 Sep 20	2,697	249	986	404
30 Jun 20	2,707	-50	1,000	403
31 Mar 20	2,700	-53	1,010	396
31 Dec 19	2,693	-55	1,021	389
30 Sep 19	2,605	176	1,003	363
30 Jun 19	2,516	406	986	337
31 Mar 19	2,432	397	970	319
31 Dec 18	2,348	388	954	302
30 Sep 18	2,258	365	931	292
30 Jun 18	2,167	343	909	281
31 Mar 18	2,090	307	883	274
31 Dec 17	2,012	270	858	266
30 Sep 17	1,923	243	821	264
30 Jun 17	1,834	217	785	262
31 Mar 17	1,753	221	752	247
31 Dec 16	1,671	226	719	231
30 Sep 16	1,623	229	703	214
30 Jun 16	1,575	233	687	196
31 Mar 16	1,548	211	676	194
31 Dec 15	1,520	189	666	193
30 Sep 15	1,468	165	651	192
30 Jun 15	1,416	140	636	191
31 Mar 15	1,374	147	606	189
31 Dec 14	1,332	154	577	187
30 Sep 14	1,310	155	557	190
30 Jun 14	1,287	156	537	193
31 Mar 14	1,284	149	543	194
31 Dec 13	1,282	142	549	196

양질의 수익: IPN 은 높은 수익을 보유하고 있습니다.

이익 마진 증가: IPN 의 현재 순이익 이익률 (19.3%) 작년보다 높습니다 (12.4%).

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: IPN 의 수익은 지난 5년 동안 매년 23.9% 씩 크게 증가했습니다.

성장 가속화: 지난 1년간 IPN 의 수익 증가율( 63.4% )은 연간 평균( 23.9% 초과합니다. ).

수익 대 산업: 지난 1년간 IPN 수익 증가율( 63.4% )은 Pharmaceuticals 업계 -19.9% 초과했습니다.

Ipsen 과거 수익 실적

과거 기준 확인 5/6

주요 정보

최근 과거 실적 업데이트

Ipsen S.A. to Report Fiscal Year 2024 Results on Feb 13, 2025

First half 2024 earnings: EPS and revenues miss analyst expectations

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Ipsen S.A. to Report Q4, 2023 Results on Feb 08, 2024

Ipsen S.A. to Report First Half, 2024 Results on Jul 24, 2024

First half 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Recent updates

Ipsen S.A. to Report Fiscal Year 2024 Results on Feb 13, 2025

What Ipsen S.A.'s (EPA:IPN) P/E Is Not Telling You

Ipsen Provides Update on CONTACT-02 Phase III Trial in Metastatic Castration-Resistant Prostate Cancer Following Final Overall Survival Analysis

These 4 Measures Indicate That Ipsen (EPA:IPN) Is Using Debt Reasonably Well

Ipsen Receives CHMPPositive Opinions for Iqirvo® (Elafibranor) in Primary Biliary Cholangitis and Kayfanda® (Odevixibat) in Alagille Syndrome, Two Rare Cholestatic Liver Diseases

First half 2024 earnings: EPS and revenues miss analyst expectations

Ipsen S.A. Upgrades Earnings Guidance for the Full Year 2024

An Intrinsic Calculation For Ipsen S.A. (EPA:IPN) Suggests It's 42% Undervalued

Genfit S.A. Announces the Successful Corporate Milestone with U.S. FDA Accelerated Approval of Ipsen's Iqirvo for Primary Biliary Cholangitis

Ipsen S.A. Approves Dividend, Payable on 3 June 2024

Ipsen (EPA:IPN) Has Announced A Dividend Of €1.20

Upcoming dividend of €1.20 per share

We Think Shareholders May Consider Being More Generous With Ipsen S.A.'s (EPA:IPN) CEO Compensation Package

Ipsen (EPA:IPN) Has Affirmed Its Dividend Of €1.20

Ipsen Announces Executive Changes

Ipsen (EPA:IPN) Has Affirmed Its Dividend Of €1.20

Dividend of €1.20 announced

There's Reason For Concern Over Ipsen S.A.'s (EPA:IPN) Price

Ipsen (EPA:IPN) Seems To Use Debt Quite Sensibly

Ipsen’s Onivyde Regimen, Potential New Standard-Of-Care First-Line Therapy in Metastatic Pancreatic Adenocarcinoma, Approved by FDA

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Ipsen Announces Latest Phase III Trial Data Investigating Cabometyx®? in Combination with Immunotherapy to Be Present at ASCO Gu 2024

Investors Still Waiting For A Pull Back In Ipsen S.A. (EPA:IPN)

These 4 Measures Indicate That Ipsen (EPA:IPN) Is Using Debt Reasonably Well

Ipsen Confirms U.S. FDA Grants Priority Review for New Drug Application for Elafibranor for the Treatment of Rare, Cholestatic Liver Disease, PBC

Ipsen and GENFIT Announces Full Results from the Pivotal Phase III ELATIVE Trial

Ipsen S.A. to Report Q4, 2023 Results on Feb 08, 2024

Ipsen S.A. to Report First Half, 2024 Results on Jul 24, 2024

Are Investors Undervaluing Ipsen S.A. (EPA:IPN) By 31%?

These 4 Measures Indicate That Ipsen (EPA:IPN) Is Using Debt Reasonably Well

IRLAB Therapeutics AB Announces Further Information on Results from Mesdopetam’s Clinical Phase IIb Study in Parkinson’s Disease Levodopa-Induced Dyskinesias and Phase III Preparatory Phase I Studies Performed by Ipsen

First half 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Profit margin trend

Ipsen Provides Update on E.U. Marketing Authorization Application for Bylvay for Cholestatic Pruritus in Patients with Alagille Syndrome

Ipsen Announces European Commission Decision on Palovarotene for the Treatment of FOP

Ipsen and GENFIT Announces Positive Results from Phase III ELATIVE Trial of Elafibranor in Patients with Primary Biliary Cholangitis, A Rare Cholestatic Liver Disease

Is There An Opportunity With Ipsen S.A.'s (EPA:IPN) 34% Undervaluation?

Ipsen Announces U.S. FDA Submission Acceptance of Its Supplemental New Drug Application for Onivyde Regimen in First-Line Metastatic Pancreatic Ductal Adenocarcinoma

Ipsen Announces U.S. FDA Approves Bylvay® for Patients Living with Cholestatic Pruritus Due to Alagille Syndrome

Ipsen to Present New Data

Ipsen (EPA:IPN) Is Due To Pay A Dividend Of €1.20

Ipsen S.A. Approves Dividend, Payable on 6 June 2023

Upcoming dividend of €1.20 per share at 1.1% yield

Ipsen's (EPA:IPN) Dividend Will Be €1.20

Ipsen S.A. Proposes Final Dividend for the Financial Year 2022, Payable on June 6, 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

Ipsen S.A. (EPA:IPN) Shares Could Be 48% Below Their Intrinsic Value Estimate

Ipsen (EPA:IPN) Has A Pretty Healthy Balance Sheet

Full year 2022 earnings: EPS and revenues miss analyst expectations

Ipsen S.A. Provides Earnings Guidance for the Full Year 2023

Ipsen Receives CHMP Negative Opinion for Palovarotene as a Treatment for Fibrodysplasia Ossificans Progressiva in E.U

Ipsen Presents Phase III NAPOLI 3 Trial of Onivyde(R) Regimen Demonstrating Positive Survival Results in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma At Asco GI

Ipsen (EPA:IPN) Ticks All The Boxes When It Comes To Earnings Growth

Ipsen S.A. (ENXTPA:IPN) entered into a definitive merger agreement to acquire Albireo Pharma, Inc. (NasdaqCM:ALBO) for approximately $870 million.

Ipsen S.A. Provides Update on Phase III CONTACT-01 Trial Evaluating Cabozantinib

Is There An Opportunity With Ipsen S.A.'s (EPA:IPN) 46% Undervaluation?

Ipsen Announces Onivyde® Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

We Think Ipsen (EPA:IPN) Can Manage Its Debt With Ease

Ipsen S.A. Provides Earnings Guidance for the Financial Year 2023

Ipsen S.A. to Report Fiscal Year 2022 Results on Feb 09, 2023

Ipsen S.A. to Report Q2, 2023 Results on Jul 27, 2023

Ipsen S.A. to Report Q3, 2022 Results on Oct 26, 2022

Does Ipsen (EPA:IPN) Deserve A Spot On Your Watchlist?

Ipsen Announces Results from Phase III RESILIENT Trial Evaluating Onivyde in Second-Line Monotherapy for Small Cell Lung Cancer

Does Ipsen (EPA:IPN) Have A Healthy Balance Sheet?

First half 2022 earnings released

Ipsen S.A. Upgrades Earnings Guidance for the Full Year 2022

Here's Why We Think Ipsen (EPA:IPN) Might Deserve Your Attention Today

Ipsen Announces U.S. FDA Priority Review for Palovarotene New Drug Application in Patients with Fibrodysplasia Ossificans Progressiva Following Resubmission